ESTRO 36 Programme book and exhibition guide

Session 1: What are the methodological and practical challenges associated with the collection and use of PROMs? 08:55-09:25 Selection of measures; Time points; Electronic vs paper B. Holzner (AU) 09:25-09:35 Translation into different languages S. Davidson (UK) 09:35-09:55 Patient understanding and non-compliance T. Holch (UK)

08:55-09:55

Coffee break

09:55-10:25

Session 2: Implementation of PROM in research and clinical practice in different cancer sites 10:25-10:50 Prostate and lung cancer A. Henry (UK) 10:50-11:15 Breast and head and neck cancer P. Bidstrup (DK) 11:15-11:40 Gynaecological cancer S. Davidson (UK) 11:40-12:05 REQUITE study (radiogenomics) C. West (UK)

10:25-12:05

Lunch

12:05-13:05

Session 3: Using PROMs and dose-volume parameters to understand treatment complications 13:05-13:35 The advantages of using PROMs as the basis for complication probability modelling J. Deasy (USA) 13:35-14:05 Role of PROMs in the model-based selection of patients for

13:05-14:05

proton therapy H. Langendijk (NL)

Session 4: ePROMs 14:05-14:35 eRAPID: feasibility of completion during and six months post treatment T. Holch (UK) 14:35-15:05 OPTIMAL: longitudinal follow up using ePROMS A. Gilbert (UK)

14:05-15:35

Programme and Exhibition Guide | PROGRAMME

49